Subscribe

Meeting Highlights

San Francisco, CA—Approximately 80% of patients with stage II colon cancer will be cured by surgery alone, but 20% will still relapse. Oncologists struggle with the question of which patients could benefit from adjuvant chemotherapy to reduce this risk, and which patients can be safely observed, without further treatment.

Results of a multicenter phase 1 study of the combination of bendamustine, a bifunctional alkylating agent that is approved for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma, with lenalidomide and dexamethasone in 26 patients with refractory or relapsed MM who had received a mean of 3 (range, 2-7) prior therapies were presented. Among 21 evaluable patients, 63% achieved ≥PR (including 16% VGPR), 15% achieved MR, and 32% had SD. Grade 3/4 AEs included neutropenia and prolonged QTc interval (1 patient).1

 

Page 2 of 4
Results 11 - 20 of 39
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology